Clazakizumab - Vitaeris

Drug Profile

Clazakizumab - Vitaeris

Alternative Names: ALD 518; ALD518-003; BMS-645429; BMS-945429

Latest Information Update: 04 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alder Biopharmaceuticals
  • Developer Alder Biopharmaceuticals; Cedars-Sinai Medical Center; Medical University of Vienna; Vitaeris
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Inflammation; Psoriatic arthritis; Renal transplant rejection; Rheumatoid arthritis
  • Suspended Anaemia; Cachexia; Fatigue; Stomatitis
  • No development reported Crohn's disease; Graft-versus-host disease

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 16 Apr 2018 Alder Biopharmaceuticals terminates a phase I/II trial in line with the endpoint committee charter for Graft-versus-host disease in USA (IV) (NCT01530256)
  • 26 Feb 2018 Vitaeris has patent protection for clazakizumab, its compositions and uses and nucleic acids encoding clazakizumab in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top